Nykode Therapeutics – Q1 2024 Financial Results – presentation Posted on May 14, 2024 (May 14, 2024) by Alexandra Deschner […] Read More… from Nykode Therapeutics – Q1 2024 Financial Results – presentation
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer Posted on May 14, 2024 (May 13, 2024) by Alexandra Deschner […] Read More… from Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer
Nykode Therapeutics – Q1 2024 Financial Results Posted on May 14, 2024 (May 14, 2024) by Alexandra Deschner […] Read More… from Nykode Therapeutics – Q1 2024 Financial Results
Nykode Therapeutics – Q1 2024 Financial Results – webcast Posted on May 14, 2024 (May 14, 2024) by Alexandra Deschner […] Read More… from Nykode Therapeutics – Q1 2024 Financial Results – webcast
Nykode Therapeutics reports Q1 2024 Financial Results Posted on May 14, 2024 (May 13, 2024) by Alexandra Deschner […] Read More… from Nykode Therapeutics reports Q1 2024 Financial Results
Nykode Therapeutics – invitation to Q1 2024 financial results presentation Posted on May 7, 2024 (May 6, 2024) by Alexandra Deschner […] Read More… from Nykode Therapeutics – invitation to Q1 2024 financial results presentation
7th International Neoantigen Summit – May 2024 | Optimizing RNA/DNA-Based Vaccine Design by Identifying Key Characteristics to Ensure Success of the Therapy Posted on May 1, 2024 (May 1, 2024) by Alexandra Deschner […] Read More… from 7th International Neoantigen Summit – May 2024 | Optimizing RNA/DNA-Based Vaccine Design by Identifying Key Characteristics to Ensure Success of the Therapy
NYKODE THERAPEUTICS CALLS FOR ANNUAL GENERAL MEETING – MAY 2024 Posted on April 25, 2024 (April 24, 2024) by Alexandra Deschner […] Read More… from NYKODE THERAPEUTICS CALLS FOR ANNUAL GENERAL MEETING – MAY 2024
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer Posted on April 19, 2024 (April 18, 2024) by Alexandra Deschner […] Read More… from Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
Nykode Therapeutics – Annual Report 2023 Posted on April 19, 2024 (April 18, 2024) by Alexandra Deschner […] Read More… from Nykode Therapeutics – Annual Report 2023